

1 **Title:** CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated  
2 immune response

3  
4 **Authors:** Daniele Biasci<sup>1,\*</sup>, Martin Smoragiewicz<sup>1,\*</sup>, Claire M. Connell<sup>1,3,\*</sup>, Zhikai  
5 Wang<sup>2,\*</sup>, Ya Gao<sup>2</sup>, James Thaventhiran<sup>1</sup>, Bristi Basu<sup>3</sup>, Lukasz Magiera<sup>1</sup>, Isaac T. Johnson<sup>1</sup>, Lisa  
6 Bax<sup>3</sup>, Aarthi Gopinathan<sup>1</sup>, Christopher Isherwood<sup>1</sup>, Ferdia Gallagher<sup>4</sup>, Maria Pawula<sup>1</sup>, Irena  
7 Hudecova<sup>1</sup>, Davina Gale<sup>1</sup>, Nitzan Rosenfeld<sup>1</sup>, Petros Barmounakis<sup>5</sup>, Elizabeta Cristina Popa<sup>6</sup>,  
8 Rebecca Brais<sup>7</sup>, Edmund Godfrey<sup>4</sup>, Fraz Mir<sup>8</sup>, Frances Richards<sup>1</sup>, Douglas T. Fearon<sup>2,5,\*\*</sup>,  
9 Tobias Janowitz<sup>1,2,9,\*\*,#</sup>, Duncan Jodrell<sup>1,3,\*\*</sup>.

10  
11 \*Joint first authors

12 \*\*Joint senior authors

13 # corresponding author

14

## 15 **Affiliations**

16 <sup>1</sup>Cancer Research UK Cambridge Institute and Cancer Research UK Major Centre, University of  
17 Cambridge, Li Ka Shing Centre, Cambridge, UK.

18 <sup>2</sup>Cold Spring Harbor Laboratory, New York, USA.

19 <sup>3</sup>Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge,  
20 UK.

21 <sup>4</sup>Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge,  
22 UK.

23 <sup>5</sup>Department of Statistics Athens University of Economics and Business, Athens, Greece

24 <sup>6</sup>Weill Cornell Medicine, New York, USA

25 <sup>7</sup>Department of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge,

26 UK.

27 <sup>8</sup>Clinical Pharmacology Unit, University of Cambridge, Cambridge, UK.

28 <sup>9</sup>Northwell Health Cancer Institute, New York, USA.

29

30

31

## 32 **Abstract**

33 Inhibition of the chemokine receptor CXCR4 in combination with blockade of the PD-1/PD-L1  
34 T cell checkpoint induces T cell infiltration and anti-cancer responses in murine and human  
35 pancreatic cancer. Here we elucidate the mechanism by which CXCR4 inhibition effects the  
36 tumor immune microenvironment. In human immune cell-based chemotaxis assays, we find that  
37 CXCL12-stimulated CXCR4 inhibits the directed migration mediated by CXCR1, CXCR3,  
38 CXCR5, CXCR6, and CCR2, respectively, chemokine receptors expressed by all the immune  
39 cell types that participate in an integrated immune responses. Inhibiting CXCR4 in an  
40 experimental cancer medicine study by one-week continuous infusion of the small molecule  
41 inhibitor, AMD3100 (plerixafor), induces an integrated immune response that is detected by  
42 transcriptional analysis of paired biopsies of metastases from patients with microsatellite stable  
43 colorectal and pancreatic cancer. This integrated immune response occurs in three other  
44 examples of immune-mediated damage to non-infected tissues: rejecting renal allografts,  
45 melanomas clinically responding to anti-PD1 antibody therapy, and microsatellite instable  
46 colorectal cancers. Thus, signaling by CXCR4 causes immune suppression in human PDA and  
47 CRC by impairing the function of the chemokine receptors that mediate the intratumoral  
48 accumulation of immune cells.

49

## 50 **Statement of significance**

51 Continuous infusion of AMD3100, an antagonist of the chemokine receptor, CXCR4, induces an  
52 integrated anti-cancer immune response in metastases of patients with microsatellite stable  
53 pancreatic and colorectal cancer that is predictive of response to T cell checkpoint inhibition.

## 54 **Introduction**

55 T cell checkpoint antagonists that target the regulatory membrane proteins on T cells, CTLA-4  
56 and PD-1, have demonstrated the therapeutic potential of the immune system in cancer. Clinical  
57 responses, however, have been limited to subsets of patients with certain cancers (1–4). Lack of  
58 cancer cell antigenicity (5), dysfunction of cytotoxic CD8<sup>+</sup> T cells (6), and systemic immune  
59 modulation (7,8) have been some of the potential explanations for resistance of these cancers to  
60 T cell checkpoint inhibitors. A more general immunological principle in which mesenchymal  
61 cells may control the immune response to immunogenic epithelial tissues should also be  
62 considered (9).

63

64 The presence of tertiary lymphoid structures (TLSs) in human adenocarcinomas correlates with  
65 better long-term clinical outcome and clinical response to T cell-checkpoint inhibitors (10–13),  
66 suggesting that organized intratumoral lymphoid structures promote anti-tumor immune  
67 reactions. Mesenchymal stromal cells organize B and T cells in both secondary and tertiary  
68 lymphoid structures mainly by producing chemokines: CCL19 and CCL21 from fibroblastic  
69 reticular cells (FRCs) recruit CCR7-expressing lymphocytes and dendritic cells (DCs), and  
70 CXCL13 from follicular dendritic cells (FDCs) attracts CXCR5-expressing T and B cells (14).  
71 Notably, these two stromal cell types develop from an embryonic precursor that expresses the  
72 membrane protein, Fibroblast Activation Protein-  $\alpha$  (FAP), and may be developmentally related  
73 to the FAP-expressing fibroblastic stromal cell type that resides in solid tumors, which is termed  
74 the cancer-associated fibroblast (CAF) (15–18). CAFs also affect the trafficking of lymphocytes  
75 by producing a chemokine, CXCL12 (19), but in a manner that opposes the effects of lymphoid  
76 tissue stromal cells, by suppressing the intra-tumoral accumulation of T cells (20). Indeed,

77 continuous inhibition of CXCR4 in a mouse model of pancreatic cancer leads to T cell  
78 infiltration of the tumors and results in response to anti-PD-L1 antibody administration (20).  
79 Therefore, whether the tumor stroma supports or suppresses immune activation may depend on  
80 the relative contributions of these related stromal cell types. A pre-dominance of CAFs would  
81 suppress local immunity, whereas the presence of FRCs and FDCs and the development of TLSs  
82 would enhance intratumoral immunity. This concept has been supported by pre-clinical studies  
83 in which immune control of tumor growth in mice occurred after FAP+ CAFs were conditionally  
84 depleted (18,20).

85  
86 Here we report the results from a proof of concept experimental medicine study in which we  
87 tested the immunological consequences of inhibiting CXCR4 in patients with cancers that have  
88 historically resisted immunotherapy, micro-satellite stable (MSS) colorectal cancer (CRC) or  
89 pancreatic ductal adenocarcinoma (PDA). We report that continuous administration for one  
90 week of AMD3100 (plerixafor, Mozobil™), a small molecule inhibitor of CXCR4, promotes an  
91 integrated immune response in metastatic lesions from these patients.

92

## 93 **Results**

94 *Colorectal and pancreatic cancer cells display a CXCL12 “coat”*

95 In murine PDA tumors, cancer cells display a “coat” of CXCL12, the chemokine that FAP+  
96 CAFs produce to mediate their immune suppressive activity (20). We assessed whether such a  
97 CXCL12-coat is displayed on human PDA or CRC cancer cells by examining tumor tissue  
98 microarrays. Fluorescently labeled anti-CXCL12 antibodies stained the KRT19-expressing  
99 cancer cells in formalin fixed paraffin embedded (FFPE) tissue sections of human PDA and CRC

100 (Fig. 1).

101

102 *CXCL12 stimulated CXCR4 inhibits the directed migration of human immune cells mediated by*  
103 *chemokine receptors*

104 We assessed whether CXCL12 stimulation of CXCR4 altered the trafficking of human immune  
105 cells by performing *in vitro* transwell migration assays using Boyden chambers. We generated  
106 human cell lines that co-expressed CXCR4 with the chemokine receptors that mediate the  
107 directed migration of innate and adaptive immune cells: CXCR1 in Jurkat-CXCR4/CXCR1 cells,  
108 CXCR3 in HSB2DP-CXCR4/CXCR3 cells, CXCR5 in Raji-CXCR4/CXCR5 cells, CXCR6 in  
109 Jurkat-CXCR4/CXCR6 cells, and CCR2 in Molm13-CXCR4/CCR2 cells, respectively (Fig. 2  
110 and Fig. S1). These chemokine receptors and their respective chemokines mediate the directed  
111 migration of neutrophils (CXCR1; CXCL8), T cells, dendritic cells, and NK cells (CXCR3;  
112 CXCL9 and CXCL10), B cells (CXCR5; CXCL13), tissue-resident memory T cells (CXCR6;  
113 CXCL16), and monocytes and macrophages (CCR2; CCL2) (Fig. 2). Including CXCL12 in the  
114 upper chamber of the Boyden two chamber assay inhibited the migration of the human immune  
115 cells co-expressing CXCR4 with each one of the five other chemokine receptors towards its  
116 relevant chemokine in the lower chamber. The inhibition was dependent on CXCR4 expression  
117 (Fig. S1) and was unidirectional, in that stimulating the relevant immune cell lines with their  
118 respective chemokines for CXCR1, CXCR3, CXCR5, CXCR6 or CCR2 did not abolish the  
119 CXCR4-mediated chemotactic response to CXCL12 (Fig. 2). Incubating HSB2DP-  
120 CXCR4/CXCR3 cells with CXCL12 followed by removal of the chemokine restored the ability  
121 of cells to migrate in response to a CXCL10 gradient (Fig. S2).

122

123 *AMD3100 suppresses CXCL12-stimulated inhibition of other chemokine receptors*

124 In previous murine studies a continuous plasma concentration of 2 µg/ml (4 µM) AMD3100  
125 unmasked anti-PDA immunity and led to reduced tumor growth rates and synergy with anti-PD-  
126 L1 treatment (20). We thus examined the effect of AMD3100 in chemotaxis studies across this  
127 range of drug concentration in these human cell lines. AMD3100 fully inhibited the CXCR4-  
128 mediated chemotactic responses of all immune cell lines (Fig. 3). The CXCR4 inhibitor also  
129 fully reversed the inhibition by CXCL12 of the chemotactic functions of CXCR1 and CXCR6 on  
130 the CXCR4-expressing Jurkat cells (Fig. 3). The functions of CXCR3, CXCR5 and CCR2 were  
131 only partially restored, which correlated with the inhibitory effects of AMD3100 on CXCR3-,  
132 CXCR5-, and CCR2- mediated chemotaxis in the absence of CXCL12 (Fig. S3). This inhibitory  
133 effect of AMD3100 may be caused by partial agonism of CXCR4, which has been reported (21).  
134 Since CXCR1, CXCR3, CXCR5, CXCR6 and CCR2 mediate the trafficking of neutrophils, T  
135 cells, NK cells, DCs, B cells, tissue-resident memory T cells and monocytes, these observations  
136 suggest that AMD3100 may alter the trafficking of multiple immune cell types within tumors,  
137 thereby inducing an integrated immune response to the cancer cells. We tested this hypothesis in  
138 an experimental medicine study.

139

140 *Experimental medicine study of continuous AMD3100 infusion: Study design, recruitment and*  
141 *patient characteristics*

142 We targeted the CXCL12/CXCR4 interaction using AMD3100 in an experimental medicine  
143 study of the immunological role of CXCR4 signaling in patients with MSS CRC and MSS PDA  
144 (NCT02179970). AMD3100 has a plasma half-life of approximately 8 hours. To achieve  
145 continuous inhibition of CXCR4, as has been recommended for other chemokine receptors (22),

146 AMD3100 was delivered by continuous intravenous infusion for 7 days with the target steady-  
147 state plasma concentration being approximately 2 µg/ml (4µM). We assessed the  
148 pharmacokinetics, pharmacodynamics, and intratumoral immunological changes during  
149 treatment using serial blood tests, clinical imaging modalities, and investigations from paired  
150 biopsies taken prior to and at the end of the AMD3100 infusion (Fig. S4 and Fig. S5A).  
151  
152 We enrolled 26 patients at two centers, 24 at the Cambridge University Hospitals NHS  
153 Foundation Trust and two at Weill Cornell Medicine/New York Presbyterian Hospital. The  
154 patient eligibility criteria are shown in the Materials and Methods section. The characteristics of  
155 all enrolled patients are summarized in Table 1. On histopathological review, one patient was  
156 found to have predominantly neuroendocrine cancer cells in the biopsy tissue and this patient  
157 was therefore excluded from all analyses other than the safety and pharmacokinetic analysis. The  
158 remaining 25 patients had treatment-refractory, histologically confirmed MSS PDA (n=10) or  
159 MSS CRC (n=15). An important inclusion criterion was the presence of a baseline lymphocyte  
160 count above the lower limit of normal ( $1.0 \times 10^9/L$ ) at screening, because of concerns relating to  
161 adequate immune status and resolution of immunosuppression after previous chemotherapy.  
162 Twenty-four patients with CRC or PDA were treated with AMD3100 (one registered patient did  
163 not commence study drug, because of a disease related adverse event (AE)): 17 in the dose  
164 escalation phase (two, PDA; 15, CRC) and seven further patients with PDA in the dose  
165 expansion phase. We confirmed the presence of the CXCL12-coat in all patients enrolled in the  
166 dose escalation phase who had evaluable tissue (Fig. S6).

167

168 *Pharmacokinetic and toxicity results*



169 The first dose level of AMD3100 was an iv infusion at a rate of 20 µg/kg/hr, with subsequent  
170 patients enrolled at dose cohorts of 40, 80, and 120 µg/kg/hr, using a 3+3 design. There were no  
171 Dose Limiting Toxicities (DLTs) identified in the 20, 40 and 80 µg/kg/hr dose cohorts, but 2  
172 patients experienced DLTs at the 120µg/kg/hr dose (Table S1). One patient had a vasovagal  
173 reaction (grade 3) in the context of pain shortly after the Day 8 biopsy and prior to completion of  
174 the AMD3100 infusion. One patient who had peritoneal disease developed severe abdominal  
175 pain (grade 3), hypotension (grade 3), and a vasovagal reaction (grade 3) on day 2 of the  
176 infusion. Symptoms resolved within 24 hr after discontinuing the drug, medications for pain  
177 control, and IV fluids. Continuous infusion of AMD3100 has been reported to be associated with  
178 vasovagal reactions (23), and these events were classified as DLTs. A complete list of graded  
179 AEs is included in the supplemental material (Table S2).

180  
181 In the trial of continuous IV infusion of AMD3100 for one week in 40 patients with HIV, a  
182 single patient experienced premature ventricular contractions (23). Thus, in the current study, all  
183 patients were admitted for the initial 72 hrs of the AMD3100 infusion for continuous cardiac  
184 telemetry monitoring, and Holter monitoring thereafter. No cardiac rhythm disturbances were  
185 identified at the 80 µg/kg/hr infusion rate chosen for the expansion phase. Minor changes  
186 (Table S2) were only possibly drug related, and there were no cardiac AEs that required drug  
187 interruption and all resolved without sequelae. Therefore, hospital-based telemetry is not  
188 indicated in future studies using this infusion protocol and static ECGs and ambulatory Holter  
189 monitoring should provide sufficient cardiac monitoring.

190  
191 The dose rate of 80 µg/kg/hr yielded the target plasma level of ~2 µg/ml (4µM), and was chosen

192 for the expansion cohort which resulted in a mean steady state plasma concentration of 2.3  $\mu\text{g/ml}$   
193 (SD  $\pm$  0.9  $\mu\text{g/ml}$ ) AMD3100 in patients enrolled at this dose rate (Fig. S5B, Table S3). This  
194 infusion rate was overall well tolerated (Table S2).

195

### 196 *Pharmacodynamic and clinical results*

197 In accordance with the well characterized biological role of CXCL12/CXCR4 ligation for the  
198 retention of hematopoietic stem cells and immature leukocytes in the bone marrow (24), CD34<sup>+</sup>  
199 and other leukocyte populations were elevated during the period of AMD3100 infusion. These  
200 changes had almost completely resolved by day 28 of the study, 20 days after discontinuation of  
201 the infusion (Fig. S7). By conventional CT scanning on day 20-24, no complete or partial  
202 responses were identified in 23 evaluable patients. Thirteen patients (57%) had stable disease  
203 and 10 (43%) disease progression. Paired PET-CT scans were evaluable in 19 participants (12  
204 escalation phase, 7 expansion phase). Of these, 11 participants had CRC and 8 PDA. Clinically  
205 significant (defined as delta Standardized Uptake Values mean weighted average (SUV MWA)  $\geq$   
206 30%) changes were seen in 2 participants. Both were patients with CRC (treated at 40  $\mu\text{g/kg/hr}$ )  
207 and had a  $\geq$ 30% increase in SUV MWA (71% and 32%).

208

### 209 *Immunological analysis of metastatic tissue from pre-treatment and on-treatment biopsies*

210 We performed immunological analyses on all patients who had sufficient sample material for  
211 comparative histopathological and RNA studies (PDA n=4; CRC n=10) (Fig. S4). We first  
212 sought histological evidence of an immunological response to CXCR4 inhibition by determining  
213 the frequency of CD8<sup>+</sup> T cells in paired pre- and end-of-treatment biopsies of metastatic lesions.  
214 FFPE tissue sections were stained with antibodies specific for CD8 $\alpha$  and keratin (pan-CK),

215 respectively (Fig. 4A). There was a significant increase in the number CD8<sup>+</sup> T cells in the pan-  
216 CK<sup>+</sup> cancer cell areas after treatment with AMD3100 (Fig. S8A). Frozen samples of different  
217 biopsy passes of the same metastatic lesions were subjected to bulk RNA-Seq analysis. The  
218 CD8a mRNA levels were significantly upregulated after AMD3100 administration (Fig. S8B),  
219 and significantly correlated with the histopathologically determined CD8<sup>+</sup> T cell frequencies  
220 (Fig. 4B). This validation of the quantitative RNA-Seq transcriptomic set justified the further  
221 analysis of this comprehensive source of immunological data.

222  
223 By enrichment analysis of the RNA-Seq data, we found that continuous inhibition of CXCR4 by  
224 infusion of AMD3100 induced intra-tumoral T and NK cell accumulation and activation (Fig.  
225 4C) and also induced an activated B cell response. Eighteen of the 100 most differentially  
226 expressed genes were derived from the B cell lineage. The upregulated expression of transcripts  
227 encoding the J chain, heavy chain constant regions, and TNFRSF17, when taken together with  
228 the more modest increased expression of MS4A1 (CD20), CD19, TNFRSF13B and  
229 TNFRSF13C suggests that this response is more a consequence of plasma cell differentiation  
230 than an accumulation of B cells (Table S4). A plasma cell transcriptional signature in breast and  
231 lung adenocarcinomas has been shown to correlate with improved survival (25). This  
232 AMD3100-induced T and B cell response was accompanied by transcriptional evidence for the  
233 development of TLSs (Fig. 4D and E, Table S4). The restriction of CCL19 mRNA, which is  
234 expressed only by FRCs (26), to tumor stromal cells that were FAP<sup>+</sup>, a marker not only of CAFs  
235 but also of FRCs (15,27), was demonstrated by fluorescent *in situ* hybridization (FISH). The  
236 FAP<sup>+</sup> cells expressing CCL19 increased significantly from 5.8% to 25.7% (Fig. 4D), suggesting

237 either that CAFs were differentiating to FRCs within the tumor microenvironment, or that FRCs  
238 were being recruited from a source outside the tumors.

239

240 *The INTegrated Immune REsponse (INTIRE) and immune-mediated damage to non-infected*  
241 *tissues*

242 The similarity of the AMD3100-induced transcriptional changes to those that characterize  
243 tumors with TLSs (Fig. 4E), micro-satellite instable (MSI) CRC (Fig. 4F), and rejecting renal  
244 allografts (Fig. 4G) suggested that the inhibition of a single chemokine receptor, CXCR4, may  
245 induce an integrated immune reaction that is characteristic of non-infected, immunogenic tissues.

246 To assess the integrated immune response, we developed the INTIRE gene signature which was

247 defined by 194 genes that together identify nine components of innate and adaptive immunity

248 (Table S5): Monocyte/Macrophage/DC/Antigen Presentation, T and NK Cell Accumulation, T

249 and NK Effector Cells, Chemokines and Chemokine Receptors, Activated B Cells (Germinal

250 Center B Cells) and Plasma Cells, Stromal/FRC/TLS, Type I/III Interferon Response, and

251 Endothelial Cells (blood and lymphatic). AMD3100 treatment of MSS PDA and MSS CRC

252 patients induced the INTIRE gene signature (Fig. 5A). Upregulation of the INTIRE gene panel

253 also was associated with decreased expression of E2F target genes and other genes involved in

254 the G2M checkpoint, possibly indicating a reduction in replicating cancer cells in the tumor. The

255 INTIRE gene signature also distinguished between rejecting and non-rejecting renal allografts in

256 two studies (28,29), a prototypical example of immunologically mediated damage to non-

257 infected tissue. Relative to MSS CRC, MSI CRC demonstrated the INTIRE gene signature (Fig.

258 5A) (30,31), but, in contrast to the effects of inhibiting CXCR4 in MSS CRC and MSS PDA,

259 MSI CRC did not exhibit decreased Cell Cycle gene expression (Fig. 5A). The INTIRE gene

260 signature was also present in tumors from longer surviving patients in the data from the  
261 PREdiction of Clinical Outcomes from Genomic Profiles (PRECOG) study (Fig. 5B) (25). In  
262 two studies of melanoma patients treated with anti-PD-1 antibody after 28 days and 11 days,  
263 respectively (32,33), and a study of melanoma patients treated with combination anti-PD-1 plus  
264 anti-CTLA-4 antibodies (33), responders demonstrated the INTIRE gene signature. Remarkably,  
265 the INTIRE gene signature also distinguished between melanomas that subsequently responded  
266 to treatment with anti-PD-1 antibody from those that did not (32,33) (Fig. 5A and C). Finally,  
267 melanomas in patients who were depleted of B cells by administration of anti-CD20 (34)  
268 demonstrated an attenuated INTIRE gene signature (Fig. 5A and D), exemplifying the integrated  
269 nature of this immune response.

270

#### 271 *Immune-mediated anti-cancer effects of AMD3100 administration*

272 We examined the transcriptional changes in the paired biopsies for evidence of intratumoral  
273 immune mediated anti-cancer effects. Changes in the mRNA levels in biopsies from each patient  
274 of granzymes (GZM) A, B, H, K, and M and perforin, which encode the proteins that mediate  
275 killing by effector CD8<sup>+</sup> T cells, significantly inversely correlated with changes in the mRNA  
276 levels of three genes uniquely expressed by cancer cells, CEACAM 5, 6, and 7 (Fig. 6A), but not  
277 with non-cancer-specific genes (Fig. S9).

278

279 Next we evaluated plasma biomarker evidence of anti-cancer effects in all samples that passed  
280 the respective quality thresholds for analysis. The plasma concentrations of the tumor-derived  
281 markers, carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (Ca19-9), which are  
282 not validated as early response markers in immunotherapy trials, were not significantly changed

283 over the 7 day treatment period of the patients with AMD3100 (n=15, p=0.4). Next, we  
284 quantified circulating tumour DNA (ctDNA). Levels of ctDNA have been shown to decrease  
285 when patients respond to therapy (35–38). We evaluated ctDNA levels at baseline and after 7  
286 days of treatment with AMD3100 (Fig. 6B). ctDNA levels were significantly reduced following  
287 treatment with AMD3100 (n=15, p=0.033). Furthermore, plasma levels of CXCL8, which has  
288 also been identified as a marker of tumour burden (39) and may provide an early indicator of  
289 therapeutic response (39–41), were also significantly decreased following treatment with  
290 AMD3100 (Fig. 6C, n=18, p<0.0001). The decrease in both ctDNA and CXCL8 levels support  
291 the possibility of an early anti-cancer effect mediated by CXCR4 inhibition.

292

## 293 **Discussion**

294 The findings that the CAF mediates intratumoral immune suppression (18,20) and that a CAF-  
295 derived chemokine, CXCL12, coats the cancer cells in PDA and CRC suggest that its receptor,  
296 CXCR4, has a role in mediating immune suppression in the tumor microenvironment. The  
297 association of CXCL12 with cancer cells is predicted to have two immunological consequences.  
298 First, most immune cells in PDA and CRC tumors express CXCR4 and will, therefore, be  
299 stimulated by cancer cell-associated CXCL12 via ligation of this receptor. Second, CXCL12-  
300 stimulated CXCR4 inhibits the chemotactic functions of the chemokine receptors that direct the  
301 migration of immune cells. Therefore, the CXCL12-coat of cancer cells could impair the intra-  
302 tumoral accumulation of multiple immune cell types. We tested these two predictions in an  
303 experimental medicine study in which patients with PDA and CRC received the, small molecule  
304 CXCR4 antagonist, AMD3100, which is licensed for mobilization of hematopoietic stem cells.

305

306 Treatment of patients with AMD3100 was limited to continuous iv infusion of the drug for one-  
307 week, using a protocol shown to be safe in patients with HIV (23). We first confirmed that the  
308 AMD3100 infusion did achieve continuous CXCR4 inhibition by observing the presence of  
309 CD34<sup>+</sup> HSCs in the peripheral blood of each patient. All patients from the dose escalation phase  
310 showed persistent elevations of CD34<sup>+</sup> HSCs, indicating the occurrence of continuous CXCR4  
311 inhibition, and we therefore included patients from the entire cohort in all subsequent analyses.  
312 The short duration of drug administration limited our ability to observe whether CXCR4  
313 inhibition induced clinical responses in patients with PDA or CRC, as assessed by standard  
314 radiological evaluations (42,43). These assessments did not reveal remissions and the lack of  
315 change in tumor volume is not informative due to the short time period that elapsed between  
316 scans. An independent clinical trial testing discontinuous CXCR4 inhibition by subcutaneous  
317 administration of a cyclic peptide inhibitor of CXCR4 together with anti-PD-1 antibody over  
318 several cycles in patients with advanced pancreatic cancer showed some evidence of clinical  
319 responses (44). We observed significant decreases in the levels of ctDNA and circulating  
320 CXCL8 of patients after treatment with AMD3100. ctDNA and CXCL8 are increasingly  
321 recognized as markers of tumour burden (35,38,39) and may provide early indications of  
322 response to therapy (35–41), when imaging evaluation is not conclusive (42,43). However, these  
323 initial observations will require further prospective validation.

324

325 This study focused on the question of whether the CXCL12-coating of cancer cells in PDA and  
326 CRC signified the existence of a fundamental immune suppressive pathway in two human  
327 cancers that have thus far resisted cancer immunotherapy. We chose to detect immunological  
328 changes by performing bulk RNASeq analysis of paired biopsies of metastatic lesions taken from

329 patients before and at the end of the AMD3100 infusion. This analysis provided an unbiased and  
330 quantitative means of measuring the AMD3100-induced changes in the complex intratumoral  
331 immune environments of these tumors, which could be compared to similar transcriptional  
332 analyses of tissues representing other immunological reactions.

333

334 This comparative transcriptional analysis revealed unanticipated similarities between the  
335 immunological effects of two mechanistically distinct immunotherapies, inhibition of T cell  
336 checkpoints and inhibition of a chemokine receptor, respectively, in cancers that have different  
337 developmental origins, adenocarcinomas and melanomas. Both anti-PD-1 and anti-CTLA-4  
338 antibody therapies, which enhance the activation of T cells, and AMD3100 treatment, which  
339 affects the trafficking of immune cells, up-regulated the expression of genes that characterize  
340 rejecting renal allografts, an example of immune damage to immunogenic, non-cancer tissue.  
341 Thus, effective cancer immunotherapy engages an immune pathway that mediates damage to  
342 non-infected, immunogenic tissue. This pathway involves multiple immune elements, and their  
343 participation could be assessed by the INTIRE signature, which characterizes nine components  
344 of the immune reaction. This analysis showed that the INTIRE signature was induced not only  
345 by CXCR4 inhibition in patients with PDA and CRC, but also by successful treatment of patients  
346 with melanoma with anti-PD-1 antibody. The occurrence of the INTIRE signature was even  
347 predictive of subsequent clinical responses to anti-PD-1 antibody therapy in patients with  
348 melanoma. The additional finding that AMD3100 leads to the increased frequency of FAP+  
349 cells expressing CCL19, which is a characteristic of FRCs, is consistent with the concept that  
350 shifting the balance from immune suppressive fibroblastic cells to those with immune-enhancing  
351 functions improves the outcome of cancer immunotherapy. This observation is reminiscent of the



352 recent reports that the presence of TLSs, which in the mouse requires FAP+ fibroblasts (15, 45),  
353 correlates with clinical responses to T cell checkpoint therapy (11–13).

354

355 Finally, the study raises the possibility that a substantial proportion of patients with MSS PDA  
356 and MSS CRC have on-going anti-cancer immune responses. A majority of the patients treated  
357 with AMD3100 showed enhanced intra-tumoral immune B and T cells responses after only  
358 seven days, which would be unusually rapid for a primary immune response. Thus, intra-  
359 tumoral immune suppression rather than immune ignorance may be a major barrier to clinically  
360 effective immunotherapy. This possibility should be assessed with an appropriate clinical trial of  
361 repeat cycles of continuous CXCR4 inhibition in combination with a T cell checkpoint  
362 antagonist.

## 363 **Acknowledgements**

364 We thank all patients.

365 The study was carried out at/supported by the NIHR Cambridge Clinical Research Facility.

366

367 We acknowledge support from the Human Research Tissue Bank, supported by the NIHR

368 Cambridge Biomedical Research Centre, for sample processing, and the Histopathology Core

369 Facility at the CRUK CI for sample immunostaining and imaging.

370

371 We thank Purity Bundi, Breanna Demestichas, Nikos Demiris, Kate Donoghue, Alex Overhill,

372 Richard Houghton, and Eva Serrao for help with data acquisition, trial management, and data

373 illustration and Hannah Meyer for critical appraisal of the manuscript.

374

375 Funding: SU2C-Lustgarten Foundation Dream Team. Cancer Research UK Institute core grants

376 C14303/A17197 and C9545/A29580. The Li Ka Shing Centre in which some of this research

377 was performed was generously funded by CK Hutchison Holdings Limited, the University of

378 Cambridge, Cancer Research UK, The Atlantic Philanthropies and a range of other donors.

379 Individual funding acknowledgements:

380 DIJ, FR: CRUK C14303/A17197 and C9545/A29580

381 TJ: CRUK C42738/A24868; National Institutes of Health USA 5P30CA045508-31; Pershing

382 Square Innovation Fund.

383 CMC: Experimental Medicine Initiative Clinical Lectureship

384

385

386 Conflict of Interest: Sanofi provided study drug for the clinical trial and validation of the PK  
387 assay, but had no part in study design, data acquisition, data analysis, or manuscript preparation.

388

389 Current employment:

390 MS: Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

391 LM: AstraZeneca, R&D Oncology, The Anne McLaren Offices, C/O Academy House, Central

392 Cambridge, 136 Hills Road, Cambridge CB2 0QH.

393

## 394 **Methods**

### 395 *Immunofluorescence of human tumor arrays*

396 Formalin fixed, paraffin embedded (FFPE) human pancreatic and colorectal tumor arrays (US  
397 Biomax) were deparaffinized in Xylene, washed three times with ethanol, and rehydrated in a  
398 serial concentration of ethanol (from 95% to 50%) and finally in water. For antigen retrieval, the  
399 sections were boiled in 10 mM Tris, pH 8.8 plus 1 mM EDTA for 10 minutes followed by  
400 cooling down for 30 minutes, a wash with PBS, and blocking with 1% BSA/PBS at room  
401 temperature for 1 hour. Following two washes with 0.05% Tween-20/PBS and one with PBS,  
402 Alexa Fluor 568 conjugated anti-KRT19 antibody (Abcam, ab203445) and FITC conjugated  
403 anti-CXCL12 antibody (R & D Systems, IC350F) were applied and the sections were incubated  
404 at room temperature for 1 hour. Finally, the sections were stained with DAPI (Thermo, R37606)  
405 for 10 minutes and washed with 0.05% Tween-20/PBS for two times and once with PBS,  
406 followed by application of mounting medium (Thermo, P36961) and imaging with Leica SP8  
407 confocal microscope. Images were analyzed and exported through ImageJ.

408

### 409 *Chemotaxis assays*

#### 410 *Plasmids*

411 To generate lentiviral plasmid expressing human chemokine receptors, CXCR1 and CXCR3  
412 cDNA from CXCR1-Tango (Addgene, #66259) and CXCR3-Tango (Addgene, #66261),  
413 respectively, were amplified and subcloned into lentiCas9-blast (Addgene, #52962) with  
414 restriction enzymes AgeI and BamHI to replace SpCas9; CXCR5 and CXCR6 cDNA from  
415 CXCR5-Tango (Addgene, #66263) and CXCR6-Tango (Addgene, #66264), respectively, were  
416 amplified and subcloned into lentiCas9-puro to replace SpCas9 where blasticidin resistant gene

417 (blast) was also replaced with puromycin resistant gene (puro). For CRISPR editing, control  
418 guide (sgScramble, GCTTAGTTACGCGTGGACGA) and guides targeting to human *CXCR4*  
419 gene (sgCXCR4-1, TGACATGGACTGCCTTGCAT; sgCXCR4-2,  
420 CAACCACCCACAAGTCATTG; sgCXCR4-3, CAGGACAGGATGACAATACC) or human  
421 *RGS14* gene (sgRGS14-1, GCAGGGATCTGTGAGAAACG; sgRGS14-2,  
422 TCGGCAGCCCTGACGCCACG; sgRGS14-3, CTGAGACTCTCGGCGCAAGG) were cloned  
423 into the vector lentiCRISPR-v2 (Addgene, #62961).

#### 424 *Cell lines*

425 Jurkat cells (ATCC, Clone E6-1, TIB-152) were transduced with lentivirus expressing human  
426 CXCR1, CXCR3 or CXCR6, followed by treatment with 5 µg/ml blasticidin (CXCR1 and  
427 CXCR3) or 0.5 µg/ml puromycin (CXCR6) for two weeks, to generate Jurkat-CXCR4/CXCR1  
428 cells, Jurkat-CXCR4/CXCR3 cells and Jurkat-CXCR4/CXCR6 cells, respectively. For Raji B-  
429 CXCR4/CXCR5 cells, Raji B cells (ATCC, CCL-86) were transduced with CXCR5 lentivirus  
430 followed by selection with 0.5 µg/ml puromycin for two weeks. Sub-population of CCRF-HSB-2  
431 cells (ATCC, CCL 120.1) that spontaneously express high level of CXCR3 were FACS sorted as  
432 HSB2DP-CXCR4/CXCR3 cells, where DP stands for “double positive”. The Molm13 cell line  
433 (Molm13-CXCR4/CCR2) which expresses both CXCR4 and CCR2 spontaneously was a gift  
434 from Dr. Vakoc’s laboratory. For CRISPR knock-outs, Jukat-CXCR4/CXCR3 and Molm13-  
435 CXCR4/CCR2 cells were transduced with lentivirus expressing SpCas9 and control guide  
436 (sgScramble), guides targeting to CXCR4 (sgCXCR4) or RGS14 (sgRGS14). HSB2DP-  
437 CXCR4/CXCR3 cells were cultured in IMDM medium (ATCC, 30-2005) supplemented with  
438 10% FBS (Seradigm, 1500-500), 100 units/ml penicillin and 100 µg/ml streptomycin. All the

439 other cell lines were cultured in RPMI-1640 medium (ATCC, 30-2001) plus 10% FBS and  
440 penicillin/streptomycin. Cells were maintained at the density of  $1 \times 10^5$ - $1 \times 10^6$  cells/ml.

#### 441 *Flow cytometry*

442 For each cell line,  $1 \times 10^5$ - $1 \times 10^6$  cells were pellet and washed with cold FACS buffer (PBS, 2%  
443 FBS and 20 mM HEPES, pH 7.4), followed by Fc receptor blocking with Human TruStain FcX  
444 (BioLegend, 422301) in the FACS buffer at 4°C for 30 min. Cells were then stained with APC  
445 conjugated anti-Human CXCR4 antibody (BioLegend, 306510) and/or Alexa Fluor 488  
446 conjugated anti-Human CXCR1 antibody (BioLegend, 320616), PE conjugated anti-Human  
447 CXCR3 antibody (BioLegend, 353706), FITC conjugated anti-Human CCR2 antibody  
448 (BioLegend, 357215), FITC conjugated anti-Human CXCR5 antibody (BioLegend, 356913),  
449 APC conjugated anti-Human CXCR6 antibody (R & D Systems, FAB699A) for another 30 min  
450 at 4°C. Then, cells were washed with the FACS buffer twice and analyzed with BD LSRForsseta  
451 cell analyzer.

#### 452 *Chemotaxis assays*

453 The chemotaxis buffer for HSB2DP-CXCR4/CXCR3 cells is IMDM medium plus 0.1% BSA  
454 and 20 mM HEPES, pH 7.5 and for all other cell lines is RPMI-1640 medium plus 0.1% BSA  
455 and 20 mM HEPES, pH 7.5. After collection, cells were washed for two times and re-suspended  
456 in the chemotaxis buffer at the density of  $1 \times 10^6$ /ml, followed by incubation at 37°C for 30 min.  
457 For the CXCL12 cross-inhibition of the other chemokine induced chemotaxis, 80  $\mu$ l cells with or  
458 without 100 ng/ml (200 ng/ml for CCR2) recombinant human CXCL12 (R & D Systems, 350-  
459 NS) were loaded in the upper wells of the Boyden chamber plate (VWR, 89089-934; Supplier  
460 NO. 3388, 5  $\mu$ m membrane pore size), and the lower chambers were flowed in 240  $\mu$ l  
461 chemotaxis buffer with PBS or the other specific recombinant human chemokine. To test the

462 effect of other specific chemokine on the CXCL12 induced chemotaxis, cells and the specific  
463 chemokine were loaded on the upper chamber, with CXCL12 containing chemotaxis buffer  
464 loaded in the lower chamber. To evaluate the activity of AMD3100 (Sigma, A5602) on CXCL12  
465 or the other specific chemokine induced chemotaxis, cells were pre-treated with increasing dose  
466 of the drug at 37°C for 30 min, then the cell/AMD3100 mixture was loaded in the upper  
467 chambers, and CXCL12 or other specific chemokine containing chemotaxis buffer was loaded in  
468 the lower chambers. For the AMD3100 rescue of the CXCL12 mediated cross-inhibition, the  
469 AMD3100 pre-treated cells together with 100 ng/ml CXCL12 were loaded in the upper  
470 chambers, and chemotaxis buffer containing the other specific chemokine was flowed in the  
471 lower chambers. After the experiments were set up, the Boyden chamber plates were incubated  
472 at 37°C for 2 or 3 hours. Then, the number of cells in the lower chamber was counted with a  
473 Guava bench-top flow cytometer, for 30 seconds at medium flow rate (~1.2 µl/s). The  
474 concentration of each chemokine used is as following: CXCL8 (R & D Systems, 208-IL), 20  
475 ng/ml; CXCL10 (R & D Systems, 266-IP), 1000 ng/ml; CXCL13 (R & D Systems, 801-CX),  
476 1000 ng/ml; CXCL16 (R & D Systems, 976-CX), 50 ng/ml; CCL2 (R & D Systems, 279-MC),  
477 200 ng/ml.

#### 478 **RNA sequencing analysis**

##### 479 ***Gene expression quantification and differential gene expression analysis***

480 Sequences of human transcripts were downloaded from Ensembl release 97. Transcripts  
481 quantification was performed using Kallisto ver. 0.43 and gene-level count matrices for use in  
482 DESeq2 were calculated using *tximport* as recommended by DESeq2 authors (46). All  
483 subsequent analyses on gene expression were performed using R 3.5.0. For differential  
484 expression analysis, raw counts were used directly in DESeq2. For other downstream analyses

485 (i.e. fold-change correlation plots) counts data were transformed using the variance stabilizing  
486 transformation (VST) as implemented in DESeq2.

#### 487 *Gene set enrichment analysis (GSEA)*

488 Gene set enrichment analysis was performed using the *fgsea* package available in Bioconductor.  
489 GSEA plots were obtained using a modified version of the associated *plotEnrichment* function.  
490 All gene sets used in the manuscript are provided as supplementary table. Data used for Figure  
491 5A was obtained from several different sources: the rejecting allografts gene list was obtained  
492 from GEO series GSE48581 (29) and GSE36059 (28); the microsatellite instability gene list was  
493 obtained by combining Xena UCSC TCGA gene expression data (31) and MSI status for the  
494 same tumor samples (30); the list of genes associated with pan-cancer survival was obtained  
495 from the PRECOG portal (25); the anti-PD1 response gene lists were obtained from GEO:  
496 GSE91061 (32) and ENA: PRJEB23709 (33); the anti-CD20 gene list was obtained from Array  
497 Express: E-MTAB-7473 (34).

#### 498 *Code availability*

499 The authors declare that the R code used to generate the analysis presented in this study is  
500 available upon reasonable request.

501

### 502 **Experimental medicine study**

#### 503 *Patient eligibility*

504 Patients with advanced or metastatic pancreatic adenocarcinoma (PDA), high grade serous  
505 ovarian cancer (HGSOC) or colorectal adenocarcinoma (CRC), refractory to or declining  
506 conventional chemotherapy were eligible for the dose escalation phase. The 10-patient expansion  
507 cohort at the recommended phase 2 dose (RP2D) of 80 µg/kg/hr was restricted to patients with



508 PDA. Other eligibility criteria included a lesion accessible to biopsy, Eastern Cooperative  
509 Oncology Group (ECOG) performance status of 0 or 1, and adequate organ function including a  
510 lymphocyte count above the lower limit of normal. Patients were excluded if they had significant  
511 cardiac co-morbidities, such as past history of significant rhythm disturbance. Full eligibility  
512 criteria can be viewed at <https://clinicaltrials.gov/ct2/show/NCT02179970>. Patients were accrued  
513 at Cambridge University Hospitals NHS Foundation Trust and Weill Cornell Medicine/New  
514 York Presbyterian Hospital, NY, USA.

### 515 *Study design*

516 This phase 1, multicentre, open-label, non-randomized study used a 3+3 dose escalation design.  
517 The primary endpoint was the safety (evaluated using the Common Terminology Criteria for  
518 Adverse Events (CTCAE) 4.03) of AMD3100 administered, to achieve a plasma AMD3100  
519 concentration at steady state  $\geq 2\mu\text{g/ml}$  in  $\geq 80\%$  of patients at the RP2D. AMD3100 was  
520 administered as a 7-day continuous infusion. Dose-limiting toxicity (DLT) was defined as an  
521 adverse reaction (AR)  $\geq G3$  occurring within 21 days of AMD infusion. Secondary endpoints  
522 included overall response rate (RECIST 1.1) at 14 (+/-2) days after the infusion, and metabolic  
523 changes in tumor using [ $^{18}\text{F}$ ]FDG-PET/CT within 1 day of infusion completion. Baseline scans  
524 were performed within 14 days before the start of the infusion. Exploratory objectives included  
525 the assessment of immune changes in tumor biopsies. Patients were monitored by cardiac  
526 telemetry for the initial 48hr of the infusion (later amended to 72hr), followed by Holter  
527 monitoring for the remainder of the infusion.

528 Patients provided written informed consent to Research Ethics Committee-approved protocol  
529 (REC reference 15/EE/0014 at the UK center and IRB number 1508016466 at the US center), in  
530 compliance with Good Clinical Practice (GCP), local regulatory requirements and legal

531 requirements. A Clinical Trial Authorisation (CTA) was obtained from the Medicine and  
532 Healthcare Regulatory Authority (MHRA). The study was sponsored by Cambridge University  
533 Hospitals NHS Foundation Trust and the University of Cambridge and Weill Cornell  
534 Medicine/New York Presbyterian Hospital.

535 *AMD3100 sample and pharmacokinetic analysis*

536 AMD3100 plasma concentration was assessed at the following nominal time points: pre-dose,  
537 24, 72 and 168 hrs of the infusion. A time point at day 7 (+/-2) after infusion discontinuation was  
538 added from patient 1017 onwards. The concentration data were generated using a liquid  
539 chromatography-tandem mass spectrometry (LC-MS/MS) method, that met the requirements of  
540 the EMA guidance on method validation, performed by the CRUK Cambridge Institute  
541 PK/Bioanalytics Core Facility. A claim of GCP compliance is made for the sample analysis data,  
542 pending the demonstration of long-term storage stability, which is on-going at the time of  
543 publication. AMD3100 calibration standards were prepared in the range of 40-4,000 ng/mL  
544 using blank control human plasma obtained from the NHS blood transfusion service (lower limit  
545 of quantification (LLOQ) 40 ng/mL). After the addition of the internal standard (AMD3100-D4)  
546 and EDTA (10mM), plasma samples, quality control (QC) and calibration standards were  
547 extracted by protein precipitation with 1% formic acid in methanol. A portion of the supernatant  
548 was evaporated to dryness and the residue reconstituted in 1% formic acid in water prior to  
549 analysis on the LC-MS/MS. High-performance liquid chromatography was performed with the  
550 Shimadzu Nexera X2 using a Phenomenex Kinetex F5 column (1.7 $\mu$ m, 100 x 2.1mm) and  
551 mobile phases A and B containing 0.1% formic acid in water or methanol, respectively. MS/MS  
552 detection was carried out using a Sciex API6500 mass spectrometer with an electrospray source.  
553 QC samples (120, 400 and 3000 ng/mL) were used to determine the precision (coefficient of

554 variation [%CV]) and accuracy (relative error [%RE]). QC intra-day %CV was  $\leq 9.8\%$ , and  
555 %RE ranged between -3.1 to 4.8%. All instrument control and data collection was performed  
556 using Analyst v1.6.2, and peak area integration, regression and quantification using  
557 MultiQuant™ v3.0.2. A weighted (1/x<sup>2</sup>) least square linear regression was used to construct the  
558 calibration line.

559

### 560 **Pharmacodynamic analysis**

561 At baseline, 24/72/168hr of the infusion, and 21(+/-2) days after infusion, blood was collected  
562 into Sarstedt EDTA blood tubes and CD34+ cells quantified by flow cytometry. The CD34+  
563 absolute count was derived from a bead-based assay using BD Bioscience Trucount tubes and an  
564 ISHAGE gating strategy.

565

### 566 **Positron Emission Tomography**

567 Positron Emission Tomography (PET) was performed in conjunction with low dose Computed  
568 Tomography (CT) for attenuation correction and localization purposes. Images were acquired  
569 from the midbrain to the knees, approximately 90 (89.7  $\pm$  21.1) min after the injection of  $\sim 370$   
570 (368  $\pm$  13) MBq of [18F]fluorodeoxyglucose ([18F]FDG). The baseline [18F]FDG-PET/CT was  
571 performed before or at least 24 hours after the core tissue biopsy, and the post treatment PET/CT  
572 was performed within 24 hours after the biopsy on day 8 of the study. 19 patients underwent  
573 imaging at both timepoints and were evaluated for metabolic changes following treatment.  
574 Response was determined by calculating the change in the mean weighted average of the  
575 Standardized Uptake Value (SUV<sub>MWA</sub>) of the [18F]FDG avid target lesions. SUV<sub>MWA</sub> was  
576 calculated as the sum of the product of the SUV<sub>mean75%</sub> and volume for all target lesions,

577 divided by the total target lesion volume. A clinically significant change was defined as change  
578 in SUV<sub>MWA</sub>  $\geq$  30%.

579

## 580 **Biopsy processing**

### 581 *RNA and DNA extraction*

582 Snap frozen biopsies were embedded in chilled OCT (-4 °C) and allowed to solidify in a  
583 cryotome at -20 °C. Subsequently, ten 30 $\mu$ m sections were cut and collected in RLT buffer for  
584 DNA/RNA extraction, followed by six 6 $\mu$ m sections for histologic analysis. The remaining  
585 tissue was cut in 30 $\mu$ m sections until exhausted. All 30 $\mu$ m sections were extracted for DNA and  
586 RNA using the AllPrep DNA/RNA/miRNA Universal Kit (Qiagen, 80224) according to  
587 manufacturer instructions from tissues, and DNA quantification by fluorometer according to  
588 manufacturer instructions (Qubit 3.0, Life technologies). An H&E was reviewed by a  
589 Histopathologist to determine cellular content (> 40% cancer cell content).

590

### 591 *Histopathologic analyses*

592 3  $\mu$ m formalin-fixed, paraffin-embedded (FFPE) tissue sections were deparaffinised in xylene  
593 and rehydrated in an ethanol series. Immunofluorescence staining was performed on the Bond  
594 Rx automated platform. Sections were retrieved with Tris EDTA for 20 minutes and incubated  
595 sequentially with primary and secondary antibody pairs (where applicable) at room temperature  
596 for 30 minutes or, for CXCL12, 60 minutes. Slides were counterstained with DAPI and  
597 digitalized using the Axio Scan.Z1 (Zeiss) at 20 x (0.22 $\mu$ m/ pixel). Tumour areas were selected  
598 based on review of serial H&E sections by a histopathologist: liver, peritoneal fat and necrosis  
599 were excluded. The HighPlex FL v3.0.1 algorithm in Halo software (v2.3, Indica labs) was used

600 to automatically detect CD8 positive cells across all sections, with a tissue classifier that  
601 restricted analysis to pan-CK positive areas within the predefined tumour area. The same  
602 algorithm was used for pre and post treatment biopsies. Cell counts were normalised to pan-CK  
603 tissue area (cells  $\mu\text{m}^{-2}$ ).

604 Primary antibodies: CD8 (SP16; Lab Vision/Thermo Scientific), pan-cytokeratin (AE1/ AE3  
605 Alexa Fluor 488 conjugate; eBioscience), CXCL12 (79018; R&D).

606

## 607 **Immunological assays**

### 608 *Fluorescent in-situ hybridization*

609 RNAscope (Advanced Cell Diagnostics, ACD) was performed following the standard protocol.

610 Frozen sections were fixed with 4% paraformaldehyde (PFA) for 15 min at 4°C and dehydrated  
611 with sequential ethanol solution (50%-100%) at room temperature. Sections were incubated with  
612 pretreat IV for 30 min and washed in phosphate-buffered saline before being hybridized with  
613 gene-specific probes (CCL19, FAP) for 2 h at 40°C in a HybEZ oven. Sections were washed with  
614 wash buffer followed by incubations in sequential amplifiers (Amp1-Amp4). Finally, sections  
615 were stained with DAPI and mounted with prolong antifade mountant. Images were taken by  
616 Leica SP8 confocal microscope and analyzed with ImageJ software.

617

### 618 **Plasma cell-free DNA analysis**

619 Blood samples were collected into EDTA-containing tubes and processed by a double-  
620 centrifugation protocol (1,600 g for 10 minutes; 14,000 rpm for 10 minutes) before storage at -  
621 80°C. Plasma DNA was extracted using QIASymphony DSP Circulating DNA Kit (QIAGEN) and  
622 DNA sequencing libraries were prepared using the ThruPLEX Plasma-seq kit (Takara Bio).

623 Unique DNA barcode sequences were introduced to allow pooled sequencing runs on HiSeq 4000  
624 (Illumina) generating 150-bp long paired-end reads. Sequencing reads were subsequently aligned  
625 to the human reference genome (hg19) using BWA-mem. PCR and optical duplicates were marked  
626 using MarkDuplicates (Picard Tools) and excluded from downstream analysis along with reads of  
627 low mapping quality. Sequencing data in each sample were downsampled to 5 million reads to  
628 generate t-MAD scores (47) for estimating ctDNA levels inferred from a genome-wide copy  
629 number aberration profile. The segmentation step was summarized by a median value and a t-  
630 MAD threshold of 0.015 was used.

631

### 632 **Cytokine analysis**

633 Serum was analysed for CXCL8 using the MesoScale Discovery Human 10-plex  
634 ProInflammatory Panel 1 kit (V-PLEX K15049D-2), as per manufacturer's instructions.  
635 Analyses were conducted at the Core biochemical assay laboratory (CBAL) at CUH, NHS  
636 Foundation Trust.

637

## 638 **References**

- 639 1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved  
640 survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*.  
641 2010;363:711–23.
- 642 2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al.  
643 Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med*.  
644 2012;366:2443–54.
- 645 3. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and  
646 Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. *N Engl J Med*.  
647 2012;366:2455–65.
- 648 4. Sharma P, Allison JP. The future of immune checkpoint therapy. *Science*. 2015;348:56–  
649 61.
- 650 5. Schumacher TN, Scheper W, Kvistborg P. Cancer Neoantigens. *Annu Rev Immunol*.  
651 2019;37:173–200.
- 652 6. McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T Cell Exhaustion During Chronic  
653 Viral Infection and Cancer. *Annu Rev Immunol*. 2019;37:457–95.
- 654 7. Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer  
655 immunotherapy: Diagnostic tools and therapeutic strategies. *Science*. 2018;359:1366–70.
- 656 8. Flint TR, Janowitz T, Connell CM, Roberts EW, Denton AE, Coll AP, et al. Tumor-  
657 Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity. *Cell*  
658 *Metab*. 2016;24:672–84.
- 659 9. Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A  
660 framework for advancing our understanding of cancer-associated fibroblasts. *Nat Rev*

- 661 Cancer. 2020;3:174–86.
- 662 10. Germain C, Gnjjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, et al. Presence of B  
663 cells in tertiary lymphoid structures is associated with a protective immunity in patients  
664 with lung cancer. *Am J Respir Crit Care Med*. 2014;189:832–44.
- 665 11. Petitprez F, de Reyniès A, Keung EZ, Chen TWW, Sun CM, Calderaro J, et al. B cells are  
666 associated with survival and immunotherapy response in sarcoma. *Nature*. 2020;577:556–  
667 60.
- 668 12. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, et al. B cells and tertiary  
669 lymphoid structures promote immunotherapy response. *Nature*. 2020;577:549–55.
- 670 13. Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. Tertiary  
671 lymphoid structures improve immunotherapy and survival in melanoma. *Nature*.  
672 2020;577:561–5.
- 673 14. Denton AE, Linterman MA. Stromal networking: cellular connections in the germinal  
674 centre. *Curr Opin Immunol*. 2017;45:103–111.
- 675 15. Denton AE, Carr EJ, Magiera LP, Watts AJB, Fearon DT. Embryonic FAP+ lymphoid  
676 tissue organizer cells generate the reticular network of adult lymph nodes. *J Exp Med*.  
677 2019;216:2242–52.
- 678 16. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-  
679 associated fibroblasts direct tumor progression of initiated human prostatic epithelium.  
680 *Cancer Res*. 1999;59:5002–11.
- 681 17. Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal  
682 fibroblasts as a potential antibody target in human epithelial cancers. *Proc Natl Acad Sci*  
683 U S A. 1990;87:7235–9.



- 684 18. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, et al.  
685 Suppression of antitumor immunity by stromal cells expressing fibroblast activation  
686 protein-alpha. *Science*. 2010;330:827–30.
- 687 19. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al.  
688 Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth  
689 and angiogenesis through elevated SDF-1/CXCL12 secretion. *Cell*. 2005;121:335–48.
- 690 20. Feig C, Jones JO, Kraman M, Wells RJB, Deonaraine A, Chan DS, et al. Targeting  
691 CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti –  
692 PD-L1 immunotherapy in pancreatic cancer. *Proc Natl Acad Sci U S A*. 2013;110:20212–  
693 7.
- 694 21. Zhang WB, Navenot JM, Haribabu B, Tamamuraz H, Hiramatu K, Omagari A, et al. A  
695 point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse  
696 agonist and that AMD3100 and ALX40-4C are weak partial agonists. *J Biol Chem*.  
697 2002;277:24515–21.
- 698 22. Schall TJ, Proudfoot AEI. Overcoming hurdles in developing successful drugs targeting  
699 chemokine receptors. *Nat Rev Immunol*. 2011;11:355–63.
- 700 23. Hendrix CW, Collier AC, Lederman MM, Schols D, Pollard RB, Brown S, et al. Safety,  
701 pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor  
702 inhibitor, in HIV-1 infection. *J Acquir Immune Defic Syndr*. 2004;37:1253–62.
- 703 24. Peled A, Petit I, Kollet O, Magid M, Ponomaryov T, Byk T, et al. Dependence of human  
704 stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. *Science*.  
705 1999;283:845–8.
- 706 25. Gentles AJ, Newman AM, Liu CL, Bratman S V., Feng W, Kim D, et al. The prognostic

- 707 landscape of genes and infiltrating immune cells across human cancers. *Nat Med*.  
708 2015;21:938–45.
- 709 26. Siegert S, Luther SA. Positive and negative regulation of T cell responses by fibroblastic  
710 reticular cells within paracortical regions of lymph nodes. *Front Immunol*. 2012;3:285.
- 711 27. Denton AE, Roberts EW, Linterman MA, Fearon DT. Fibroblastic reticular cells of the  
712 lymph node are required for retention of resting but not activated CD8<sup>+</sup> T cells. *Proc Natl*  
713 *Acad Sci U S A*. 2014;111:12139–12144.
- 714 28. Reeve J, Sellarés J, Mengel M, Sis B, Skene A, Hidalgo L, et al. Molecular diagnosis of T  
715 cell-mediated rejection in human kidney transplant biopsies. *Am J Transplant*.  
716 2013;13:645–55.
- 717 29. Halloran PF, Pereira AB, Chang J, Matas A, Picton M, De Freitas D, et al. Potential  
718 impact of microarray diagnosis of t cell-mediated rejection in kidney transplants: The  
719 INTERCOM study. *Am J Transplant*. 2013;13:2352–63.
- 720 30. Kautto EA, Bonneville R, Miya J, Yu L, Krook MA, Reeser JW, et al. Performance  
721 evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS.  
722 *Oncotarget*. 2017;8:7452–63.
- 723 31. Goldman M, Craft B, Kamath A, Brookes A, Zhu J, Haussler D. The UCSC Xena  
724 platform for cancer genomics data visualization and interpretation. *bioRxiv*. 2018;326470.
- 725 32. Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, et al. Tumor and  
726 Microenvironment Evolution during Immunotherapy with Nivolumab. *Cell*.  
727 2017;171:934–949.e16.
- 728 33. Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, et al. Distinct Immune Cell  
729 Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4

- 730 Combined Therapy. *Cancer Cell*. 2019;35:238–55.
- 731 34. Griss J, Bauer W, Wagner C, Simon M, Chen M, Grabmeier-Pfistershammer K, et al. B  
732 cells sustain inflammation and predict response to immune checkpoint blockade in human  
733 melanoma. *Nat Commun*. 2019;10:4186.
- 734 35. Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid  
735 biopsies come of age: Towards implementation of circulating tumour DNA. *Nat Rev*  
736 *Cancer*. 2017;17:223–38.
- 737 36. Cabel L, Proudhon C, Romano E, Girard N, Lantz O, Stern MH, et al. Clinical potential of  
738 circulating tumour DNA in patients receiving anticancer immunotherapy. *Nat Rev Clin*  
739 *Oncol*. 2018;15:639–50.
- 740 37. Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, et al. Dynamics of  
741 tumor and immune responses during immune checkpoint blockade in non–small cell lung  
742 cancer. *Cancer Res*. 2019;79:1214–25.
- 743 38. Parkinson CA, Gale D, Piskorz AM, Biggs H, Hodgkin C, Addley H, et al. Exploratory  
744 Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment  
745 Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A  
746 Retrospective Study. *PLoS Med*. 2016;13:e1002198.
- 747 39. Sanmamed MF, Carranza-Rua O, Alfaro C, Oñate C, Martín-Algarra S, Perez G, et al.  
748 Serum interleukin-8 reflects tumor burden and treatment response across malignancies of  
749 multiple tissue origins. *Clin Cancer Res*. 2014;20:5697–707.
- 750 40. Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz  
751 ME, et al. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to  
752 anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. *Ann Oncol*.

- 753 2017;28:1988–95.
- 754 41. Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, et al. High systemic and  
755 tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. *Nat*  
756 *Med.* 2020;26:693–698.
- 757 42. Hodi FS, Hwu W-J, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of  
758 Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced  
759 Melanoma Treated With Pembrolizumab. *J Clin Oncol.* 2016;34:1510–7.
- 760 43. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the  
761 evaluation of immune therapy activity in solid tumors: immune-related response criteria.  
762 *Clin Cancer Res.* 2009;15:7412–20.
- 763 44. Bockorny B, Semenisty V, Macarulla T, Borazanci E, Wolpin BM, Stemmer SM, et al.  
764 BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy  
765 for pancreatic cancer: the COMBAT trial. *Nat Med.* 2020;10.1038/s41591-020-0880-x.
- 766 45. Nayar S, Campos J, Smith CG, Iannizzotto V, Gardner DH, Mourcin F, et al.  
767 Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and  
768 local pathology. *Proc Natl Acad Sci U S A.* 2019;116:13490-7.
- 769 46. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for  
770 RNA-seq data with DESeq2. *Genome Biol.* 2014;15:550.
- 771 47. Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, et al.  
772 Enhanced detection of circulating tumor DNA by fragment size analysis. *Sci Transl Med.*  
773 2018;10:eaat4921.

774 **Main figure legends**

775 **Figure 1. The CXCL12-coat of human pancreatic and colorectal cancer cells.** Sections of  
776 human pancreatic (PDA) and colorectal (CRC) adenocarcinoma were stained with fluorescent  
777 antibodies to CXCL12, and to KRT19 to reveal cancer cells. The ratios shown in the top right  
778 corners of the photomicrographs indicate the frequency of the observed staining relative to the  
779 total number of independent tumors that were assessed. Scale bar, 50  $\mu$ m.

780

781 **Figure 2. The effect of CXCL12-stimulated CXCR4 on chemokine receptor-mediated**  
782 **migration of human immune cells.** Left panels: The co-expression of CXCR4 with (A)  
783 CXCR1, (B) CXCR3, (C) CXCR5, (D) CXCR6, and (E) CCR2 on human immune cell lines was  
784 evaluated by flow cytometry after staining with antibodies specific for the relevant chemokine  
785 receptors. Gray peaks indicate isotype controls. Middle panels: The effect of CXCL12-  
786 stimulation of CXCR4 on the chemotactic responses of (A) CXCR1-co-expressing Jurkat T  
787 lymphoblastoid cells to CXCL8, (B) CXCR3-co-expressing HSB2DP T lymphoblastoid cells to  
788 CXCL10, (C) CXCR5-co-expressing Raji B lymphoblastoid cells to CXCL13, (D) CXCR6-co-  
789 expressing Jurkat T lymphoblastoid cells to CXCL16, and (E) CCR2-co-expressing Molm13  
790 monocytoid cells to CCL2 was assessed by including CXCL12 in the upper chamber (blue) and  
791 the other chemokines in the lower chamber (red) in the Boyden two-chamber assay. Right  
792 panels: The chemotaxis assays were performed with the five cell lines when the placement of the  
793 chemokines in the Boyden chambers was reversed. Bar diagrams display mean and standard  
794 error of the mean. Statistical analysis by student's t test: \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ ; ns, not  
795 significant.  
796

797 **Figure 3. Inhibition by AMD3100 of the suppression mediated by CXCL12-stimulated**  
798 **CXCR4 of the function of other chemokine receptors. Panels A-E:** The chemotactic  
799 responses were assessed of the dual chemokine receptor-expressing human immune cells to the  
800 relevant chemokines in the absence or presence of CXCL12, with increasing concentrations of  
801 AMD3100. The results are presented as percent of the chemotactic response in the absence of  
802 CXCL12 and AMD3100. The mean and standard error of the mean are indicated.  
803

804 **Figure 4. The immunological effects in human CRC and PDA of treatment with AMD3100.**

805 Paired biopsy tissues were obtained from the same metastasis in each patient before (pre-Rx) and  
806 after seven days of continuous infusion of AMD3100. **(A)** Tissue sections were stained with  
807 fluorescent antibodies to pan-keratin (pan-CK) to reveal cancer cells, and to CD8 to reveal  
808 cytotoxic T cells. White arrowheads designate CD8<sup>+</sup> T cells within cancer cell islets, and red  
809 arrowheads designate CD8<sup>+</sup> T cells outside of cancer cell islets. **(B)** The presence of CD8<sup>+</sup> T  
810 cells within cancer cell islets, assessed by staining with anti-CD8 antibody, correlates with the  
811 CD8A mRNA levels, assessed by RNAseq analysis, in tissues obtained from different pass  
812 biopsies of the same metastatic lesions. **(C)** Immunological gene sets that identify T and NK cell  
813 accumulation, T and NK cell effector cells, activated B cells (germinal center B cells) and  
814 plasma cells are enriched in genes upregulated after treatment with AMD3100. **(D)** The  
815 expression of CCL19 and FAP in sections from paired biopsies was analyzed by fluorescent in  
816 situ hybridization using specific probes for mRNA of FAP and CCL19. The total counts of  
817 FAP<sup>+</sup>/CCL19<sup>+</sup> cells, FAP<sup>+</sup>/CCL19<sup>-</sup> cells, and FAP<sup>-</sup>/CCL19<sup>+</sup> cells are displayed. **(E)** The  
818 enrichment analysis for a TLS gene set (13) is shown. **(F and G)** Enrichment analyses are shown  
819 for those genes that **(F)** are differentially expressed in rejecting compared to non-rejecting  
820 kidney allografts (28, 29) and **(G)** MSI compared to MSS CRC (30). **(A-G)** n=14 comprising of  
821 PDA (n=4) and CRC (n=10). Scale bar, 50  $\mu$ m. Statistical comparisons by Spearman's rank  
822 correlation test **(B)**, and by Fisher's exact test **(D)**: \*\*\*\*, p<0.0001.

823

824



825 **Figure 5. Comparative analyses of the integrated immune response (INTIRE) induced by**  
826 **AMD3100.** (A) The heat map is shown of the enrichment analyses of nine gene sets representing  
827 different immune components that characterize the INTIRE in different immunological contexts,  
828 along with E2F target genes and genes involved in the G2M checkpoint. Comparative  
829 enrichment analyses for differentially expressed genes in paired biopsies with differential  
830 expressed genes from (B) biopsies from patients with longer versus shorter survival based on the  
831 PRECOG (25) analysis, (C) pre-treatment biopsies from patients with melanoma who responded  
832 to anti-PD1 treatment vs. non-responding patients (32,33), and (D) pre-treatment vs. week six of  
833 treatment biopsies from patients with melanoma who were depleted of B cell by treatment with  
834 anti-CD20 antibodies (34). (A-D) n=14 comprising of PDA (n=4) and CRC (n=10).  
835

836 **Figure 6. Analyses of the anti-cancer effect induced by AMD3100 treatment.** (A) Changes of  
837 mRNA expression in the paired biopsies obtained from each patient with CRC (n=10) and with  
838 PDA (n=4) before and after treatment with AMD3100 for granzymes A, B, H, K, and M and  
839 perforin negatively correlate with changes in the expression of CEACAM 5,6, and 7. (B) Plasma  
840 ctDNA levels (n=15) and (C) serum concentrations of CXCL8 (n=18) pre-treatment (pre-Rx)  
841 and after seven days of continuous infusion of AMD3100 are shown. Statistical comparisons by  
842 Spearman's rank correlation test (A), by paired Wilcoxon signed-rank test paired (B), and by  
843 paired t-test (C): \*,  $p < 0.05$ ; \*\*\*\*,  $p < 0.0001$ .

844 **Supplementary figure legends**

845

846 **Figure S1. The inhibition by CXCL12 of CXCR3- and CCR2-mediated chemotaxis of**

847 **human immune cells depends on CXCR4 co-expression. (A)** Jurkat-CXCR4/CXCR3 T

848 lymphoblastoid cells were CRISPR/Cas9-edited with different sgRNAs and assessed for CXCR4

849 expression by FACS analysis, chemotaxis to CXCL12 in the lower Boyden chamber, and

850 chemotaxis to CXCL10 in the lower chamber in the presence of CXCL12 in the upper chamber.

851 **(B)** Molm13-CXCR4/CCR2 monocytoïd cells were CRISPR/Cas9-edited with different sgRNAs

852 and assessed for CXCR4 expression by FACS analysis, chemotaxis to CXCL12 in the lower

853 Boyden chamber, and chemotaxis to CCL2 in the lower chamber in the presence of CXCL12 in

854 the upper chamber. Statistical analysis by student's t test: \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ .

855

856 **Figure S2. The reversibility of inhibition by CXCL12 of CXCL10-induced chemotaxis.**

857 HSB2DP-CXCR4/CXCR3 T lymphoblastoid cells were treated with PBS (Ctrl) or CXCL12 at  
858 37°C for 15 minutes, followed by washing and resuspension in culture medium. After resting at  
859 37°C for timed intervals, the cells were assessed for their chemotactic responses to CXCL12  
860 (blue bars) or CXCL10 (red bars).

861

862 **Figure S3. The effect of AMD3100 on the directed migration of the dual chemokine**  
863 **receptor-expressing human cells.** The chemotactic responses of (A) Jurkat-CXCR4/CXCR1  
864 cells, (B) HSB2DP-CXCR4/CXCR3 cells, (C) Raji B-CXCR4/CXCR5 cells, (D) Jurkat-  
865 CXCR4/CXCR6 cells, and (E) Molm13-CXCR4/CCR2 cells was assessed in the presence of the  
866 indicated chemokines and increasing concentrations of AMD3100. The results are expressed as  
867 percentage of the responses occurring in the absence of AMD3100.  
868

869 **Figure S4. Consort diagram of the experimental medicine study (NCT02179970).**

870

871 **Figure S5. Schematic of the experimental medicine study and the pharmacokinetic and**  
872 **toxicity results.** (A) The study time line is shown for the experimental medicine study of  
873 continuous iv infusion of AMD3100 to patients with PDA and CRC. (B) Plasma concentrations  
874 of AMD3100 at increasing dose levels of the iv infusion on day 2, 4, and 8 of the study are  
875 displayed. The mean and standard error of the mean are indicated.  
876

877 **Figure S6. The CXCL12-coat on pancreatic and colorectal cancer cells from biopsies of**  
878 **study patients.** For patients enrolled during the dose escalation part of the study, sections of  
879 biopsies of metastases from patients with pancreatic (PDA) and colorectal (CRC)  
880 adenocarcinoma were stained with fluorescent antibodies to pan-CK to reveal cancer cells, and to  
881 CXCL12. The ratios shown in the top right corners of the photomicrographs indicate the  
882 frequency of the observed staining relative to the total number of independent tumors assessed.  
883 Scale bar, 50  $\mu\text{m}$ .  
884  
885



886 **Figure S7. The effect of continuous AMD3100 administration on peripheral blood**  
887 **leukocyte levels.** The relative levels for six leukocyte subtypes on study day two, four, eight, and  
888 28, as compared to the levels of day one, are displayed. Subdivisions by dose level of AMD3100  
889 are included for each study day. Statistical comparison of study day levels by nested ANOVA: \*,  
890  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ ; \*\*\*\*,  $p < 0.0001$ ; ns, not significant.  
891

892 **Figure S8. Quantification of immunohistochemical and transcriptional analyses of the**  
893 **frequency of intratumoral CD8<sup>+</sup> T cells.** Paired biopsies of metastases obtained from each  
894 patient with CRC or PDA were analyzed. **(A)** The frequency of CD8<sup>+</sup> T cells, assessed by  
895 immunofluorescent staining of FFPE tissue, within cancer cell islets is displayed. **(B)** The  
896 mRNA levels of CD8A, assessed by RNAseq analysis, are shown. **(A and B)** n=14 comprising of  
897 PDA (n=4) and CRC (n=10). Statistical comparisons by paired t-test **(A)**, and by Wald test **(B)**:  
898 \*, p<0.05; \*\*\*\*, p<0.0001.


899 **Figure S9. Correlation of granzymes and perforin with the expression of non-cancer-**  
900 **specific genes after AMD3100 treatment.** Changes of mRNA expression after AMD3100  
901 administration for granzymes A, B, H, K, and M and perforin compared to changes in mRNA  
902 expression for (A) EEF1A1, (B) ACTB, and (C) RPLP0 are shown. Statistical comparisons by  
903 Spearman's rank correlation test are shown.

<b>Table 1. Patient Characteristics</b>	
<b>Characteristic</b>	<b>N=26</b>
Age - yr	
Mean	66
Range	50-76
Female sex – no (%)	9 (35)
Histology - no. (%)	
Pancreatic adenocarcinoma	10 (38)
Colorectal adenocarcinoma	15 (58)
Neuroendocrine cancer <sup>¶</sup>	1 (4)
ECOG - no. (%)	
0	9 (35)
1	17 (65)
Lymphocyte count (10 <sup>9</sup> /L)	
Median	1.41
Range*	0.82-2.31
Albumin < 35 g/L - no. (%)	13 (50)
Sites of metastasis >2 - no. (%)	16 (62)
Prior lines of chemotherapy- no. (%)	
0	1(4)
1	1(4)
2	16 (62)
≥3	8 (31)


<sup>¶</sup> On central review of research biopsies, pathology consistent with neuroendocrine pancreatic cancer, excluded from later analysis

\*1 patient had a low count at enrolment that normalized on day 1 pre-infusion


**Figure 1**




**Figure 2**



**Figure 3**




**Figure 4**






**Figure 5**



**Figure 6**



## Supplemental Tables and Figures

Biasci *et al.* CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response

Dose cohort (µg/kg/hr)	Patient ID	Day of discontinuation or interruption	Adverse event	Relation to plerixafor	Action	Outcome of adverse event
40	1007	7	Biliary tract obstruction and infection	Unlikely to be related	Discontinued	Recovered
120	1013	5	Duodenal obstruction	Unlikely to be related	Discontinued	Recovered
120	1014	8	Vasovagal reaction*	Possibly related	Discontinued	Recovered
120	1018	2	Vasovagal reaction, hypotension, abdominal pain*	Possibly related	Discontinued	Recovered
80	1022	4	Panic attack	Possibly related	Discontinued	Recovered
* Dose Limiting Toxicity						

**Table S2. Drug related adverse events during dose escalation and expansion phase**

CTCAE v 4.03		Dose escalation (mcg/kg/hr)																Escalation + Expansion		
		20			40				80			120						80 mcg/kg/hr (n=11)		
Category	Term	01	02	03	04	05	07	08	09	10	11	12	13	14	15	16	17	18	G1-2 (n (%))	G3-4 (n (%))
Cardiac	Atrial fibrillation																		1 (9)	0
	Multifocal atrial tachycardia																		1 (9)	0
	Palpitations																		1 (9)	0
	Supraventricular ectopic beats																		2 (18)	0
	Supraventricular tachycardia																		1 (9)	0
	Ventricular arrhythmia																		2 (18)	0
Eye	Watering eyes																	1 (9)	0	
Gastrointestinal	Abdominal pain																	4 (36)	0	
	Abdominal distention																	8 (73)	0	
	Diarrhea																	8 (73)	0	
	Dry mouth																	1 (9)	0	
	Flatulence																	4 (36)	0	
	Nausea																	1 (9)	0	
	Vomiting																	1 (9)	0	
General	Chills																	1 (9)	0	
	Fatigue																	2 (18)	0	
	Fever																	1 (9)	0	
	Non-cardiac chest pain																	0	1 (9)	
Hematologic	Anemia																	2 (18)	0	
	Platelet count decreased																	1 (9)	0	
Infections	Oral candidiasis																	1 (9)	0	
Investigations	ALK Phosphatase increased																	1 (9)	0	
	ALT increased																	2 (18)	0	
	Creatinine increased																	1 (9)	0	
	INR increased																	2 (18)	0	
Metabolism and nutrition	Anorexia																	2 (18)	0	
	Hypoalbuminemia																	5 (45)	0	
	Hypoglycemia																	1 (9)	0	
	Hypokalemia																	1 (9)	0	
	Hypophosphatemia																	2 (18)	0	
Nervous system	Abnormal dreams																	3 (27)	0	
	Dizziness																	1 (9)	0	
	Dysgeusia																	1 (9)	0	
	Headache																	8 (73)	0	
	Paresthesia																	1 (9)	0	
	Presyncope																	1 (9)	0	
	Tremor																	1 (9)	0	
	Vasovagal reaction																	2 (18)	0	
Renal	Proteinuria																1 (9)	0		
Respiratory	Dyspnea																	1 (9)	0	
	Rhinorrhea																	1 (9)	0	
Psychiatric	Anxiety																	1 (9)	0	
	Claustrophobia																	1 (9)	0	
	Confusion																	6 (55)	0	
	Insomnia																	0	1 (9)	
	Panic attack																	4 (36)	0	
Vascular	Hot flashes/flushing																	0	1 (9)	
	Hypertension																	1 (9)	0	
	Hypotension																	1 (9)	0	

Adverse event grade 1 2 3

**Table S3. AMD3100 pharmacokinetic parameter estimates.**

<b>Dose cohort (<math>\mu\text{g}/\text{kg}/\text{hr}</math>)</b>	<b>Patients enrolled</b>	<b><math>C_{ss}</math> (<math>\mu\text{g}/\text{ml}</math>)</b>	<b><math>AUC_{0-168}</math> (<math>\mu\text{g}^*\text{h}/\text{ml}</math>)</b>	<b>CI (L/hr)</b>
20	3	0.58 (0.57-0.60)	76 (72-80)	2.86 (2.64-3.10)
40	4*	1.05 (0.74-1.32)	143 (110-174)	2.76 (2.67-2.92)
80	11#	2.28 (1.17-3.80)	324 (182-544)	2.82 (1.90-3.53)
120	7†	2.99 (2.38-4.16)	431 (359-570)	3.14 (2.45-3.74)

Mean (range)




\* Patient 1007 withdrawn at day 6, excluded

# Patient 1022 withdrawn at day 4, excluded




† Patients 1013, 1014 and 1018 withdrawn at day 5, 8, and 2, respectively, excluded.

## Figure S1


**A**




**B**



**Figure S2**



## Figure S3





**Figure S4**






Figure S5



**Figure S6**




Figure S7





Figure S8



**Figure S9**

